Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06240754 · ClinicalTrials.gov registry record · Phase 2
Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
A Phase 2 study of Clonal Cytopenia of Undetermined Significance and CCUS Clonal Cytopenia of Undetermined Significance, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06240754 is a Phase 2 study of Clonal Cytopenia of Undetermined Significance and CCUS Clonal Cytopenia of Undetermined Significance that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 15 participants, below the 435-participant average among 11 other Clonal Cytopenia of Undetermined Significance trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06240754, a Phase 2 study of Clonal Cytopenia of Undetermined Significance and CCUS Clonal Cytopenia of Undetermined Significance, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.
Conditions Studied
Interventions
- DRUG Enasidenib
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06240754
The ClinicalTrials.gov registry entry for NCT06240754 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 435-participant average among 11 other Clonal Cytopenia of Undetermined Significance trials with a reported enrollment target (97% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Clonal Cytopenia of Undetermined Significance appearing as the primary indexed condition, and to 1 intervention - of which Enasidenib is the first listed.
NCT06240754 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06240754 about?
NCT06240754 is a clinical study titled "Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial". Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective t...
What is the current status of trial NCT06240754?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2024-10-10. Estimated completion is 2029-02-28.
What conditions does trial NCT06240754 study?
This clinical trial studies the following conditions: Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance.
What interventions are being tested in trial NCT06240754?
The interventions under investigation include: Enasidenib (DRUG).
Who is sponsoring clinical trial NCT06240754?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06240754 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clonal Cytopenia of Undetermined Significance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
RECRUITING · Phase 2
-
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RECRUITING · Phase 2
-
Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
RECRUITING · Phase 2
-
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Clonal Cytopenia of Undetermined Significance
All registered trials for this condition
CCUS Clonal Cytopenia of Undetermined Significance
All registered trials for this condition
Missouri
All trials with a study site in Missouri
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.